The normal benefits associated with the treatment are not being met and so new dosing strategies should be sought.
Phase I clinical trials using oral dosing were completed in early 1999.
Patients who are stable on a once weekly dosing regimen may be switched to once every two weeks administration.
Then place the capped dosing syringe in the carrying case provided.
Normal range morning serum testosterone concentrations are reached during the first day of dosing.
